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Summary Chromosomal loss is a characteristic feature of the myelodysplastic syndromes (MDS). A method
is described which detects chromosomal 7 loss in MDS by DNA analysis using a specific hypervariable region
gene probe which has been cloned from a human DNA fingerprint. Loss of one of the chromosomal 7
homologues was demonstrated in 10/118 MDS patients; the ten patients include all the five patients which
had previously been shown to have monosomy 7 by cytogenetic analysis. This technique makes it feasible to
study serial samples from large numbers of patients for loss of chromosomal material and could be readily
applied to the study of other human malignancies.
The myelodysplastic syndromes (MDS) are a diverse group
of disorders of the haemopoietic stem cells characterised by
ineffective and dysplastic haematopoiesis in one or more cell
lines (Tricot et al., 1986). Using conventional cytogenetic
techniques about half of all MDS patients show clonal
chromosomal abnormalities (Heim & Mitelman, 1986;
Second International Workshop on Chromosomes in
Leukaemia, 1979), the most frequent cytogenetic
abnormalities being partial or complete loss of chromosome
5 or 7, and trisomy 8. The presence of specific lesions like
monosomy 7 and complex karyotypic abnormalities are
associated with a higher risk of transformation to acute
leukaemia (Michiels et al., 1986; Borgstrom, 1986; Todd &
Pierre, 1986).
For an adequate cytogenic analysis a satisfactory number
of high quality mitoses are needed and this may not always
be technically feasible. Another drawback to cytogenic
analysis is that it is not possible to determine the lineage of
cells analysed. Hence techniques are now being developed
for the detection of chromosomal loss by DNA analysis
which will complement standard cytogenetics. These methods
depend on restriction fragment length polymorphism (RFLP)
analysis to differentiate the two chromosomal homologues,
each RFLP allele being derived from one of the two
chromosomes. This type of analysis is informative if consti-
tutional DNA displays heterozygosity for a particular RFLP,
so that loss of one of these alleles in the tumour DNA
indicates chromosomal loss (Koufos et al., 1984; Orkin et al.,
1984; Reeve et al., 1984; Fearon et al., 1984).
The majority of RFLPs are due to site polymorphisms
with only two possible alleles caused by the presence or
absence of the restriction enzyme cleavage site. For such
polymorphisms at least 50% of individuals are homozygous
for one allele and hence uninformative. The problem may be
overcome by using several DNA probes for a particular
chromosomal region in the hope that the patient will be
heterozygous for at least one of the RFLPs. However, an
alternative approach is to use a single tandem-repetitive
DNA probe specific for a hypervariable chromosomal locus.
Such probes detect many different alleles at a particular
locus (the size of the allele varies with the number of copies
of the repeating unit) with the majority of individuals being
heterozygous at such loci. We demonstrate the feasibility of
this approach in a study of chromosomal 7 loss in MDS
using a hypervariable DNA probe, pAg3 which has been
localised to 7q33-qter (Wong et al., 1986; Wong et al.,
submitted; Royle & Jeffreys, unpublished data).
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Materials and methods
Patients and specimens
One hundred and sixteen patients with de novo MDS and
two patients with MDS following chemotherapy and radio-
therapy seen at the Royal Victoria Hospital, Bournemouth
and the John Radcliffe Hospital, Oxford were included in
the study. The diagnosis of myelodysplasia was made by
morphological study of peripheral blood and bone marrow
specimens and patients were classified according to the FAB
criteria (Bennett et al., 1982). All peripheral blood leucocytes
and bone marrow specimens were obtained at presentation
prior to any cytotoxic chemotherapy and whenever clinically
indicated, thereafter. In addition, where possible 15-20 hair
root follicles as a source of constitutional DNA (Pilkington
et al., 1987) were also obtained at the time of bone marrow
sampling. Peripheral blood samples were taken from 58
normal healthy British volunteers as a control group.
DNA analysis
DNA was isolated from the peripheral blood leucocytes,
bone marrow cells and hair root follicles as described (Old &
Higgs, 1983; Gill et al., 1985). DNA (3jg) was digested with
the restriction enzyme HinfI under conditions recommended
by the manufacturers (Boehringer, Mannheim). The resultant
DNA fragments were separated by electrophoresis in a 0.8%
agarose gel and then transferred to a nylon membrane
(Amersham, Hybond-N) by Southern blotting. When
available, DNA from peripheral blood leucocytes, bone
marrow cells and hair roots from each patient were electro-
phoresed in adjacent tracks.
The plasmid pAg3 was a subclone in pUC 13, containing a
large hypervariable DNA fragment isolated from a human
DNA fingerprint as described previously (Wong et al., 1986).
The probe pAg3 has been localised by somatic cell hybrid-
isation and in situ hybridisation to chromosome 7 in the
region 7q33-qter (Royle & Jeffreys, unpublished data). The
DNA probe was a 7.1 kb Sau3A insert from pAg3, contain-
ing -171 tandem repeats of a 37bp sequence plus 747bp
flanking DNA. Since it also contains the beginning of an
Alu element, human competitor DNA was included in the
hybridisations using this probe. Subsequently a 6.5kb AluI
insert, without the Alu element, was used as a hybridisation
probe and the human competitor DNA was omitted from
the hybridisation. The probes were labelled to high specific
activity by random hexanucleotide priming (Feinberg &
Vogelstein, 1983) and hybridisation was carried out at 65°C
as described (Old & Higgs, 1983). After hybridisation, filters
were washed for 30min in 0.1 x SSC and 0.1% SDS at 65°C
and autoradiographed between intensifying screens at
-700C.
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Results
Fifty-four of 58 normal individuals were heterozygous for
the pAg3 allele, four individuals being homozygous for the
common shortest allele giving a heterozygosity rate of 93%.
The majority of the MDS patients (112/118, 95%) were
heterozygous for the pAg3 allele, with only 6 patients
showing a single allele, 5 of which were of the common
shortest type. Homozygosity at this locus in 3/6 patients was
confirmed by comparison of the tumour DNA with consti-
tutional (hair root) DNA.
Chromosomal 7 loss by DNA analysis
The p)3 locus is extremely polymorphic; in a previous study
of 79 randomly-selected British Caucasians (Wong et al.,
1986) at least 77 different alleles could be resolved. In a
normal individual, the two pAg3 alleles typically display a
steady drop of intensity of hybridisation signal with
decreasing size of the alleles; the common shortest allele
typically appears much less intense than the other larger
alleles. This is related to the low number of repeating units
in the common shortest allele, a phemomenon also seen in
hybridisation with other hypervariable probes. In practice,
interpretation of the band patterns is usually straightforward
if the reduced intensity of the smaller allele in comparison to
that of the larger allele is noted. Furthermore, any intensity
difference between two alleles in tumour DNA should be
confirmed by comparison with the band patterns in
constitutional DNA.
Marked difference in relative hybridisation intensities
between the two pAg3 alleles was not observed in any of the
54 normal individuals heterozygous for this locus. In the
majority of MDS patients the two plg3 alleles were of
equivalent intensity (Figure 1). However, in ten cases the
hybridisation signal of one of the two allelic bands was
found to be much weaker indicating a loss in part or whole
or a reduplication of one of the two chromosome 7 homo-
logues. Details of the cytogenetic analysis in these ten
patients are shown in Table I; one patient was not typed,
two others were reported normal, two showed trisomy 8, two
were monosomic for chromosome 7, two showed a complex
karyotype including monosomy 7, and one showed a complex
karyotype including deletion of 7q. None of the remaining
108 patients were monosomic for chromosome 7 by cyto-
genetic analysis.
The marked reduction in hybridisation intensity of one of
the two allelic bands was particularly evident when consti-
tutional DNA from hair roots was available for comparison
as shown in patients AH, SH, RS and JC in Figure 2. As
expected, complete absence of the allele was not observed
since the DNA analysed had been isolated from a mixed
population of lymphoid and myeloid cells as well as from a
mixed population of parental and mutant cells.
Patient 8 (RS) who had refractory anaemia with excessive
blasts in transformation (RAEB-T) showed complex
chromosomal abnormalities including 7q-. She was treated
with a course of intensive cytotoxic chemotherapy. A
complete remission was achieved; analysis of the DNA with
pAg3 showed that the marked difference in hybridisation
intensities of the two alleles seen initially in the DNA sample
at presentation was no longer evident in remission and
cytogenetic studies revealed no evidence of the abnormal
clone. Patient 7 (SH) showed equal intensities of the two
pAg3 alleles in the presentation bone marrow DNA as well
as in the hair root DNA and cytogenetic analysis showed a
normal karotype; marked reduction in one of the allelic band
intensities became evident in subsequent bone marrow DNAs
and repeat cytogenetic analyses showed trisomy 8 with no
evidence of loss or deletion of chromosome 7.
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Figure 1 Autoradiograph of DNA samples from MDS patients
digested with HinfI and hybridised to pAg3 probe. Lanes 1-9
represent nine different MDS patients with sources of DNA as
indicated; PB - peripheral blood, BM - bone marrow, HR - hair
root. Lanes 3a and 3b, 6a and 6b and 7a and 7b represent DNA
from the same patient. Note that patients 2 and 8 are
homozygous for pAg3.
Table 1 Clinical and cytogenetic findings in 10 patients with myelo-
dysplasia and chromosomal 7 loss
Patient Diagnosis' Bone marrow karyotype
1. FHb RAEB-T Normal
2. MBb RAEB Not done
3. RTb CMML Normal
4. AH RA 47,XX, +8
5. LVb RAEB-T (Complex karyotype including -7)
6. IHC b RAEB 45,XX, -7
7. SHd RAEB-T 47,XX, +8
8. RS RAEB-T 43, XX, -18, -18, -19, -21, -18
+ 1-3 double minutes, 7q-,
22p+, small ring
9. jCe RAEB 45,XX, -7
10. NW" RAEB-T 47, del(lp), t(2;4), -3 del(5q), -7
+8, -11, -13, t(l4q;15q), -17, -18,
t(llp; 13q), +4 markers
'Represents subgroups of MDS according to the FAB
classification, RA - Refractory anaemia, RAEB - Refractory
anaemia with excessive blasts, CMML - Chronic myelomonocytic
leukaemia, RAEB-T - Refractory anaemia with excessive blasts in
transformation; bDead; cPresented with RA with trisomy 8,
subsequent evolution to RAEB was accompanied by monosomy 7
with spontaneous disappearance of trisomy 8; dPresented with
RAEB, cytogenetic analysis showed a normal karyotype and RFLP
analysis showed equal intensity of p).g3 alleles. At subsequent
transformation to RAEB-T, cytogenetic analysis showed trisomy 8
and RFLP analysis showed marked reduction in one of the pAg3
alleles; ePresented with secondary MDS following treatment with
Busulphan for essential thrombocythaemia; fPresented with RAEB-T
following radioactive phosphorus treatment for polycythaemia vera.CHROMOSOMAL 7 LOSS IN MYELODYSPLASIA 133
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Figure 2 Loss of heterozygosity at pAg3 locus on chromosome 7 in ten MDS patients. DNA was digested with HinfI and
hybridised to the pAg3 probe. The patients' initials are shown above the blots and correspond to details given in Table I; lanes N
represent normal individuals. The source of DNA is as indicated; PB - peripheral blood, HR - hair root, BM - bone marrow,
trans BM - BM taken during transformation of disease, pres BM - BM at presentation of disease, rem BM - BM at remission of
disease. In all the ten patients there is marked reduction in hybridisation intensity of one of the pAg3 allelic bands in tumour
DNA. Note that in patient SH trans BM represents BM a, b and c taken at consecutive times during transformation of disease.
The marked difference in hybridisation signal between the two pAg3 alleles in tumour DNA of patients FH, MB and RT was
confirmed by hybridisation of pAg3 to Alul-digested DNA where changes occurred in bands of similar sizes as expected since
HinfI and AluI cleave at 4bp sequences to each release a minisatellite in a similar sized fragment.
Discussion
Chromosomal loss is one of the major types of somatic
changes which occur in neoplastic cells. Until recently, the
loss of chromosomal material was only detectable by
cytogenic analysis. However, advances in the techniques of
DNA analysis have now provided alternative methods of
detecting such losses which are potentially very valuable
since they can be readily applied to the study of large
numbers of patients, to serial samples from individuals for
the study of disease progression, and to particular cell
populations for the study of lineage involvement.
The use of RFLPs for the detection of chromosome 7 loss
in MDS was demonstrated in a recent study (Kere et al.,
1987) in which three DNA probes which detect site poly-
morphisms (i.e. each detecting only 2 possible alleles) were
used. We present a more efficient method for the detection
of loss of chromosome 7 using a single chromosome 7
specific hypervariable DNA probe (pAg3). The hetero-
zygosity rates in both the normal individuals and the MDS
patients were extremely high, demonstrating the validity of
this approach in the distinction of the chromosomal
homologues. An added advantage of using a hypervariable
DNA probe is that the RFLP is usually detectable using a
variety of restriction enzymes unlike site polymorphisms
where the RFLP is only present for a particular restriction
enzyme cleavage site. The practical implication is that filters
can be readily rescreened with other hypervariable region
probes for other chromosomal losses.
pAg3 is localised to 7q33-qter and, therefore, is useful for
the detection of monosomy 7, complete or partial deletion
of 7q or development of homozygosity by mitotic
recombination in 7cen-7q33. Interstitial deletions of
chromosome 7 will be detected if the segment specific to this
probe is involved. Ten of the 118 (9%) MDS patients who
were informative for the pAg3 locus showed marked, unequal
intensities of the two allelic bands. This result is in keeping
with the numbers of monosomy 7 abnormalities detected in
MDS in several studies (Heim & Mitelman, 1986; Michiels et
al., 1986; Yunis et al., 1986; Jacobs et al., 1986). In fact the
ten patients who showed loss of one of the chromosome 7
homologues by RFLP analysis include all five patients
demonstrated to have full or partial monosomy 7 by cyto-
genetic analysis. There were no cases of monosomy 7,
demonstrated cytogenetically, which was not detected by
DNA analysis. It is interesting that the two patients, JC and
NW, with secondary MDS in this series both had monosomy
7. In five patients chromosomal 7 loss demonstrated by
DNA analysis was not demonstrated by cytogenetic analysis.
This could be because many patients with myelodysplasia
have poor proliferation of the abnormal clone and
metaphases may be obtained only from the residual normal
population. Since the probe is localised to 7q33-qter, it is
also possible that in these cases there is a submicroscopic
deletion of the tip of 7q which is not obvious cytogenetically.
We have shown that it is readily possible to screen a large
number of MDS patients for a particular chrosomal loss
using a single hypervariable DNA probe. The isolation of an
increasing number of hypervariable DNA probes specific for
other chromosomal regions (Wong et al., submitted) will
allow this technique to be applied more widely to the study
of other malignancies.
We thank Linda Roberts and Liz Rose for preparation of the
manuscript; J. Pearson of the Medical Genetics Department,
Churchill Hospital, Oxford for cytogenetic analysis of two of the
patients studied; Professor Sir D.J. Weatherall and Dr F.G. Bolton
for encouragement and support. SLT is a Wellcome Senior Research
Fellow in Clinical Science. JSW is supported in part by the
Leukaemia Research Fund.134 S.L. THEIN et al.
References
BENNETT, J.M., CATOVSKY, D., DANIEL, M.T. & 4 others (1982).
Proposals for the classification of the myelodysplastic syndromes.
Br. J. Haematol., 51, 189.
BORGSTROM, G.H. (1986). Cytogenetics *of the myelodysplastic
syndromes. Scand. J. Haematol., 36, 74.
FEARON, E.R., VOGELSTEIN, B. & FEINBERG, A.P. (1984). Somatic
deletion and duplication of genes on chromosome 11 in Wilms'
tumours. Nature, 309, 176.
FEINBERG, A.P., VOGELSTEIN, B. (1983). A technique for
radiolabelling DNA restriction endonuclease fragments to high
specific activity. Analyt. Biochemistry, 132, 6.
GILL, P., JEFFREYS, A.J. & WERRET, D.J. (1985). Forensic
application of DNA 'fingerprints'. Nature, 318, 577.
HEIM, S. & MITELMAN, F. (1986). Chromosome abnormalities in the
myelodysplastic syndromes. In Myelodysplastic syndromes,
Griffin, J.D. (ed) Clinics Haematol., 15, p. 10023. W.B. Saunders:
London.
JACOBS, R.H., CORNBLEET, M.A., VARDIMA, J.W., LARSON, R.A.,
LE BEAU, M.M. & ROWLEY, J.D. (1986). Prognostic implications
of morphology and karyotype in primary myelodysplastic
syndromes. Blood, 67, 1765.
KERE, J., RUUTU, T. & DE LA CHAPELLE, A. (1987). Monosomy 7 in
granulocytes and monocytes in myelodysplastic syndrome. New
Engl. J. Med., 316, 499.
KOUFOS, A., HANSEN, M.F., LAMPKIN, B.C. & 4 others (1984). Loss
of alleles at loci on human chromosome 11 during genesis of
Wilms' tumour. Nature, 309, 170.
MICHIELS, J.J., MALLIOS-ZORBALA, H., PRINS, M.E.F., HAHLEN, K.
& HAGEMEIJER, A. (1986). Simple monosomy 7 and myelo-
dysplastic syndrome in thirteen patients without previous
cytostatic treatment. Br. J. Haematol., 64, 425.
OLD, J.M. & HIGGS, D.R. (1983). Gene analysis. In The
thalassaemias, Weatherall, D.J. (ed) p. 000. Churchill
Livingstone: Edinburgh.
ORKIN, S.H., GOLDMAN, D.S. & SALLAN, S.E. (1984). Development
of homozygosity for chromosome Ilp markers in Wilms'
tumour. Nature, 309, 172.
PILKINGTON, S., SUMMERS, C., THEIN, S.L., O'CONNER, N.T.J. &
WAINSCOAT, J.S. (1987). Hair root DNA; a source of
constitutional DNA in leukaemia. Lancet, i, 112.
REEVE, A.E., HOUSIAUX, P.J., GARDNER, R.J.M., CHEWINGS, W.E.,
GRINDLEY, R.M. & MILLOW, L.J. (1984). Loss of a Harvey ras
allele in sporadic Wilms' tumour. Nature, 309, 174.
SECOND INTERNATIONAL WORKSHOP OF CHROMOSOMES IN
LEUKAEMIA (1979). Chromosomes in preleukaemia. Cancer
Genetics Cytogen. 1980, 2, 108.
TODD, W.M. & PIERRE, R.V. (1986). Preleukaemia: A long-term
prospective study of 326 patients. Scand. J. Haematol., 36, 114.
TRICOT, G., MECUCCI, C. & VAN DEN BERGHE, H. (1986). Evolution
of the myelodysplastic syndromes. Br. J. Haematol., 131, 365.
WONG, Z., WILSON, V., JEFFREYS, A. & THEIN, S.L. (1986). Cloning
a selected fragment from a human DNA 'fingerprint': Isolation
of an extremely polymorphic minisatellite. Nucleic Acids Res., 14,
4605.
WONG, Z., WILSON, V., PATEL, I., POVEY, S. & JEFFREY, A.J. (1987).
Characterisation of a panel of highly variable minisatellites
cloned from human DNA. Ann. Human Genet., 51, 269.
YUNIS, J.J., RYDEL, R.E., OKEN, M.M., ARNESEN, M.A., MAYER,
M.G. & LOBELL, M. (1986). Refined chromosome analysis as an
independent prognostic indicator in de novo myelodysplastic
syndromes. Blood, 67, 1721.